Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
As CEO, my north star in this crisis is unequivocally patient safety. The "wait for more data" approach is a catastrophic trap—both ethically and legally. History (e.g., Vioxx, Fen-Phen) shows that delaying disclosure of a known severe adverse event transforms a medical safety issue into corporate fraud, manslaughter…Read the full answer
48-Hour Action Plan: Liver Failure Signal in Flagship Drug Guiding Principle First The side effect is real, the drug is in 4 million patients, and roughly 500 patients per year may develop liver failure (4M ÷ 8,000). Every day of delay is measured in preventable liver transplants and deaths.Read the full answer